John Mascarenhas, MD, discusses key data from the SENTRY trial of selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis.
John O. Mascarenhas, MD
Advertisement
John O. Mascarenhas, MD, is a professor of medicine at the Icahn School of Medicine at Mount Sinai; as well as director of the Center of Excellence for Blood Cancers and Myeloid Disorders, director of the Adult Leukemia Program, and a member of The Tisch Cancer Institute
Articles by John O. Mascarenhas, MD
John O. Mascarenhas, MD, discusses the ongoing investigation of various targeted therapies in myeloproliferative neoplasms.
John O. Mascarenhas, MD, details the investigation of novel targeted therapies in patients with myeloproliferative neoplasms.
John O. Mascarenhas, MD, discusses the potential role of imetelstat in the treatment of patients with myelofibrosis.
John Mascarenhas, MD, outlines the ongoing phase 3 IMpact-MF trial, evaluating imetelstat in relapsed/refractory myelofibrosis.
John O. Mascarenhas, MD, discussed findings from the IMproveMF trial investigating imetelstat plus ruxolitinib in patients with higher-risk myelofibrosis.
John Mascarenhas, MD, discusses first-line treatment decisions for patients with myelofibrosis.
John O. Mascarenhas, MD, discusses evolution of JAK inhibitors in the treatment landscape of myelofibrosis.
John O. Mascarenhas, MD, discusses updates from the phase 2 MANIFEST trial in patients with myelofibrosis.
John O. Mascarenhas, MD, discusses the role of genetic testing in myeloproliferative neoplasms.
John O. Mascarenhas, MD, discusses the potential significance of pacritinib in patients with myelofibrosis.
John O. Mascarenhas, MD, discusses emerging agents in myelofibrosis.
John O. Mascarenhas, MD, discusses the need to develop curative therapies in myelofibrosis.
John O. Mascarenhas, MD, discusses the potential role of pacritinib in myeloproliferative neoplasms.
John O. Mascarenhas, MD, discusses the impact of ruxolitinib in the myelofibrosis treatment paradigm.
Advertisement
Latest Updated Articles
Dr Mascarenhas on the IMpact-MF Trial of Imetelstat in R/R MyelofibrosisSeptember 26th 2025
Dr. Mascarenhas on the Potential Role of Pacritinib in MPNsSeptember 10th 2020
Dr. Mascarenhas on the Need to Develop Curative Therapies in MyelofibrosisSeptember 25th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
As ADC Options Expand, Sequencing and Toxicity Management Become the Next Challenges in Gynecologic Oncology
3
MANGROVE Trial Shows Improved Efficacy With Zanubrutinib Plus Rituximab vs Chemo in MCL
4
Experts Outline the Evolving Role of ctDNA-Based MRD Testing Across Solid Tumors
5